Source 1primary paper2014Experimental and Therapeutic Medicine
Toolkit/bisulfite pyrosequencing
bisulfite pyrosequencing
Also known as: bisulfite pyrosequencing technology
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Bisulfite pyrosequencing is an assay method used to quantify promoter CpG DNA methylation after bisulfite treatment. In the cited study, it was used to measure methylation in the CAMK1D, CRY2, and CALM2 promoter regions in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Usefulness & Problems
Why this is useful
This method is useful for locus-specific measurement of promoter CpG methylation in biological samples. The supplied evidence supports its use for comparing methylation levels between disease and control cohorts in peripheral blood.
Problem solved
It addresses the need to measure promoter DNA methylation levels at specific genes of interest. In the cited application, it enabled assessment of methylation at CAMK1D, CRY2, and CALM2 promoters in type 2 diabetes versus matched healthy controls.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Mechanisms
bisulfite-based discrimination of methylated versus unmethylated cytosinesbisulfite-based discrimination of methylated versus unmethylated cytosinespyrosequencing-based sequence-dependent methylation quantificationpyrosequencing-based sequence-dependent methylation quantificationTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
The method, as evidenced here, involves bisulfite pyrosequencing technology applied to promoter regions of CAMK1D, CRY2, and CALM2. The reported sample source was peripheral blood from patients with type 2 diabetes and matched healthy controls; no further protocol details are provided.
The supplied evidence is limited to a single study and a single application context. No performance metrics, resolution details, throughput characteristics, or independent validation data are provided in the evidence.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
healthy controls 48patients with T2D 48
Approval Evidence
1 source1 linked approval claimfirst-pass slug bisulfite-pyrosequencing
Using bisulfite pyrosequencing technology
Source:
measurement methodsupports
Promoter CpG DNA methylation levels of CAMK1D, CRY2, and CALM2 were measured using bisulfite pyrosequencing in peripheral blood from patients with type 2 diabetes and matched healthy controls.
Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls.
Source:
Comparisons
Source-backed strengths
The evidence shows that the method can be applied to promoter CpG methylation analysis in human peripheral blood samples. It was used on defined target genes in a case-control study context, indicating suitability for targeted methylation quantification.
Compared with OMR assay
bisulfite pyrosequencing and OMR assay address a similar problem space.
Shared frame: same top-level item type
Strengths here: looks easier to implement in practice.
Compared with small-angle X-ray scattering
bisulfite pyrosequencing and small-angle X-ray scattering address a similar problem space.
Shared frame: same top-level item type
Strengths here: looks easier to implement in practice.
Compared with zebrafish spinal cord injury paradigms
bisulfite pyrosequencing and zebrafish spinal cord injury paradigms address a similar problem space.
Shared frame: same top-level item type
Ranked Citations
- 1.